Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | BCHE | P06276 | 2/20 | 0.48 |
| ▸ | GNAI3 | P08754 | 3/20 | 0.47 |
| ▸ | GNAO1 | P09471 | 3/20 | 0.47 |
| ▸ | GNAI1 | P63096 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | F2R | P25116 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2745504 | 0.96 | NAAA (0.51) | NAAABCHELMNAITGB3ITGA2B | |
| SCHEMBL2746605 | 0.91 | LMNA (0.56) | NAAABCHELMNAITGB3ITGA2B | |
| SCHEMBL2747483 | 0.86 | ITGB3 (0.47) | LMNAITGB3ITGA2BF2R | |
| SCHEMBL30919787 | 0.78 | MEN1 (0.55) | NAAALMNAITGB3ITGA2BGAA | |
| SCHEMBL2745501 | 0.78 | LMNA (0.50) | NAAABCHELMNAITGB3ITGA2B | |
| SCHEMBL10733582 | 0.77 | NAAA (0.66) | NAAABCHEGNAI3GNAO1GNAI1 | |
| SCHEMBL5540757 | 0.77 | LMNA (0.51) | NAAALMNAITGB3ITGA2BGAA | |
| SCHEMBL5542690 | 0.76 | ITGB3 (0.49) | LMNAITGB3ITGA2BGAAF2R | |
| SCHEMBL4555028 | 0.75 | NAAA (0.96) | NAAAGNAI3GNAO1GNAI1GAA | |
| SCHEMBL14215418 | 0.75 | RAB9A (0.48) | LMNAITGB3ITGA2BGAAF2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8367666-B2 | 3-carbamoyl-2-pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | SHIONOGI & CO., LTD. | 2012-08-16 | — | — | US | disclosed |
| US-8178681-B2 | methyl 3-methyl-2-{[2-oxo-1-(2-oxo-ethyl)-1,2,5,6,7,8,9,10-octahydro-cycloocta[b]pyridine-3-carbonyl]-amino}-butyrate; cannabinoid receptor agonist; antiinflammatory agent, immunostimulant, analgesic; atopic dermatitis; excellent in photostability, and have excellent transdermal and oral absorbency | SHIONOGI & CO., LTD. (JP) | 2012-05-15 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1806342-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2007-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208813-A1 | 3-CARBAMOYL-2-PYRIDONE DERIVATIVES | CNR2, CNR1, HRH4 | NAAA 657/4885BCHE 1431/4885GNAI3 958/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | NAAA 841/4885BCHE 1271/4885GNAI3 1665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.